LONDON - Avacta Group (AIM:AVCT) reported unaudited preliminary results for the year ended December 31, 2025, according to a press release issued Monday.
The clinical stage biopharmaceutical company held cash and short-term deposit balances of £16.9 million as of December 31, 2025, compared to £12.9 million a year earlier. The company raised £22.5 million in new equity during 2025 and completed an oversubscribed placing in March 2026 raising £10 million. As of April 30, 2026, cash held was £16.4 million, with the company stating its cash runway extends into the first quarter of 2027.
Avacta's AVA6103 program enrolled its first patient in the FOCUS-01 Phase 1 clinical trial in March 2026. The multicenter, open-label trial is enrolling patients with six advanced cancers selected through a collaboration with Tempus AI. The company expects initial clinical data from the AVA6103 program in late second half 2026.
The AVA6000 program continued enrolling patients in its Phase 1b trial during the period. Health authorities lifted the lifetime maximum dose requirement and agreed on dose selection for subsequent trials. The company expects clinical data from Phase 1a and 1b cohorts in the first half of 2026.
The company made several management appointments during the period, including Brian Hahn as Chief Financial Officer in January 2025, David Liebowitz as Chief Medical Officer in July 2025, and Francis Wilson as Chief Scientific Officer in February 2026. David Bryant and Richard Hughes joined as Non-Executive Directors in May 2025.
Avacta stated it is in discussions with multiple parties regarding potential partnering of its first, second and third generation assets. The company expects payload selection and clinical candidate selection in its AVA6207 program in the second half of 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
